HIM
BDTX icon

Hillsdale Investment Management’s Black Diamond Therapeutics BDTX Stock Holding History

Hillsdale Investment Management’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-63,623
Closed -$155K – 666
2025
Q4 		$155K Hold
63,623
– – ﹤0.01% 507
2025
Q3 		$241K Buy
+63,623
New +$186K 0.01% 479

Other funds holding BDTX

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Hillsdale Investment Management's BDTX Position: Q1 2026 in Review

Hillsdale Investment Management sold out of Black Diamond Therapeutics (BDTX) in Q1 2026, closing a stake of 63,623 shares — an estimated $155K sold.

Hillsdale Investment Management first reported a position in BDTX in Q3 2025 and held it in 2 quarters. The position peaked at $241K in Q3 2025. 104 funds tracked by Wall St. Rank hold BDTX as of Q1 2026.

  • Hillsdale Investment Management reported no remaining Black Diamond Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Hillsdale Investment Management sold 63,623 Black Diamond Therapeutics shares in Q1 2026, an estimated $155K.
  • Hillsdale Investment Management first reported a position in Black Diamond Therapeutics in Q3 2025 and held it in 2 quarters.
  • Hillsdale Investment Management's Black Diamond Therapeutics position peaked at $241K in Q3 2025.
  • 104 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q1 2026.

Based on Hillsdale Investment Management's 13F filing for Q1 2026, filed 4 May 2026.